Vincristine sulfate

Catalog No.S1241 Synonyms: Leurocristine

Vincristine sulfate Chemical Structure

Molecular Weight(MW): 923.04

Vincristine sulfate is an inhibitor of polymerization of microtubules by binding to tubulin with IC50 of 32 μM in a cell-free assay.

Size Price Stock Quantity  
USD 70 In stock
USD 270 In stock
USD 870 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

2 Customer Reviews

  • Plk inhibitor cooperates with chemotherapeutic agents. Conditional patched mutant tumor cells were treated with increasing concentrations of the chemotherapeutic agents vincristine alone or in combination with 10 nMol/L BI-2536. Cells were cultured for 48 hours, pulsed with 3H-Td, and harvested for analysis of 3H-Td incorporation at 66 hours.

    Cancer Research, 2013, 73(20): 6310-22 . Vincristine sulfate purchased from Selleck.

    for HXO-RB44 cells, IC50 values for VCR were changed in the different SG600 treatment groups. The results are representative of three independent  experiments and of f our replicates in each experiment.

    Int J Mol Sci 2012 13, 10736-10749 . Vincristine sulfate purchased from Selleck.

Purity & Quality Control

Choose Selective Microtubule Associated Inhibitors

Biological Activity

Description Vincristine sulfate is an inhibitor of polymerization of microtubules by binding to tubulin with IC50 of 32 μM in a cell-free assay.
Targets
Microtubules [1]
(Cell-free assay)
32 μM
In vitro

Vincristine inhibits net addition of tubulin dimers at assembly ends of steady-state microtubules with Ki of 85 nM. [1] At low concentrations, Vincristine stabilizes the spindle apparatus resulting in failure of the chromosomes to segregate leading to metaphase arrest and inhibition of mitosis. At higher concentrations, Vincristine may disrupt and induce total depolymerization of microtubules. [2] Vincristine induces apoptosis in tumor cells and inhibits SH-SY5Y cell proliferation with IC50 of 0.1 μM. Vincristine induces mitotic arrest and promots the expression of caspase-3 and -9 and cyclin B, while decreasing the expression of cyclin D. [4] Vincristine induced neurotoxicity is caused by interference with microtubule function, which results in blockage of axonal transport and thus in axonal degeneration. [5]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HepG2.2.15 M4TMe2NmdGxiVnnhZoltcXS7IFHzd4F6 NVXLOIRyOC1yLkWg{txO MkDZNlQhcA>? NHLSXFRl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImg[I9{\SCmZYDlcoRmdnSueR?= MnfXNlU3PjN5Nkm=
HepG2-HBV1.1 M1jGNGFxd3C2b4Ppd{BCe3OjeR?= NVjObFdGOC1yLkWg{txO M4\mRVI1KGh? MoHzbY5lfWOnczDhdI9xfG:|aYOg[I9{\SCmZYDlcoRmdnSueR?= M1rXUFI2PjZ|N{[5
HepG2.2.15 NV;LPFdITnWwY4Tpc44hSXO|YYm= M4nHZVAvOSEQvF2= NXvvcmtqOjRiaB?= M4nBVpBzd22xdHXzJIhmeGG2aYTpd{BDKH[rcoXzJJBzd3SnaX6g[ZhxemW|c3nvci=> NFTNSlMzPTZ4M{e2PS=>
HepG2-HBV1.1 MUfGeY5kfGmxbjDBd5NigQ>? MXywMlEh|ryP M3z3TVI1KGh? MWfwdo9ud3SnczDo[ZBifGm2aYOgRkB3cXK3czDwdo91\WmwIHX4dJJme3Orb36= MUOyOVY3Ozd4OR?=
HepG2-HBV1.1 NXnwTGRvTnWwY4Tpc44hSXO|YYm= M135WVAvOSEQvF2= NEDudoU1QCCq NYDnZW1ZeHKxbX;0[ZMh[2WubDDlfINz\XSrb36gc4YhcGWyYYTpeIl{KEJidnnyeZMhdnWlbHXvZ4Fxe2mmczDpcpN1\WGmIH;mJIhmeGG2aYTpd{BDKH[rcoXzJGRidmVicHHyeIlkdGW| M2ixcFI2PjZ|N{[5
HepG2-HBV1.1 M2fjXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHfTNoQxNjFizszN MV:xMVUh\A>? M4jDUolvcGmkaYTzJJRp\SCycn;sbYZmemG2aX;uJJRqdWViZHXw[Y5l\W62bIm= MUeyOVY3Ozd4OR?=
HepG2-HBV1.1 NFvJVGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoLsNE4yKM7:TR?= NHLKe5kyNTViZB?= MUPpcohq[mm2czD0bIUheHKxbHnm[ZJifGmxbjD0bY1mKGSncHXu[IVvfGy7 M{nVclI2PjZ|N{[5
HepG2-HBV1.1 NUjOUIFYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NU\wfIZnOC5zIN88US=> MUWxNk04OiCq MknYbY5lfWOnczDj[YxtKGO7Y3zlJIFzemW|dDDheEBUNXCqYYPl NWrBSGY1OjV4NkO3Olk>
HepG2-HBV1.1 M{DaVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmH3NE4yKM7:TR?= NV3vV4p{OTJvN{KgbC=> NYi4XWRzcW6mdXPld{Bk\WyuIHP5Z4xmKGG{cnXzeEBifCCVLYDoZZNm M{DTcVI2PjZ|N{[5
Raji MVvGeY5kfGmxbjDBd5NigQ>? MUewMlXDqM7:TR?= NF7XOY44OiCq MX7hZo9tcXOqZYOgZZV1d3CqYXf5xsA> MX6yOVQ1PjN5Nx?=
SK-MEL-28  MWfGeY5kfGmxbjDBd5NigQ>? Mnv1N|Ahdk1? M1frb|YhcA>? MoXSbY5lfWOnczDHNwKBm01iY3XscE1kgWOuZTDhdpJme3R? NGfR[IgzPTNzM{CxNC=>
H157 M1Xn[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFK1NlJKSzVyPUGuNFMhyrFiMD6wOEBucXV{TR?= MV2yOVI2PzlzMR?=
Jurkat NGKwW|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYGxMVMhdk1? M4HhO|Q5yqCq NFW0SVJFVVOR MWPk[YNz\WG|ZYOgeoli[mynIHPlcIwhdnWvYnXyd{Bld3OnIHTldIVv\GWwdHz5 M3vKN|I2OTV4MUS2
CEM NVGxbWNwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NILtRXYyNTNibl2= NG\vOFA1QMLiaB?= NIfFXWdFVVOR M1riW4Rm[3KnYYPld{B3cWGkbHWgZ4VtdCCwdX3i[ZJ{KGSxc3Wg[IVx\W6mZX70cJk> M3;DcVI2OTV4MUS2
P12 M1u5PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mm\3NU0{KG6P MUC0POKhcA>? NHTmUlBFVVOR NGfs[Whl\WO{ZXHz[ZMhfmmjYnzlJINmdGxiboXtZoVzeyCmb4PlJIRmeGWwZHXueIx6 MkL4NlUyPTZzNE[=
KB NVHHXG41T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mo\VTWM2OD1yLkCwOFkhyrFiMD6wNFAyKM7:TR?= MlnONlUxPTh3Mk[=
KBv200 (ABCB1) NFP0UIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnXJTWM2OD1yLkO0OlIhyrFiMD6wNFY3KM7:TR?= M2HBeVI2ODV6NUK2
SUDHL6  M1fkVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkHONgKBkc7:TR?= MlfhOFgwPzJiaB?= NXq2NmZJcW6qaXLpeJMh[2WubDD2bYFjcWyrdImgd4lodmmoaXPhcpRtgQ>? NIO2eWgzPDl4MU[wOC=>
SUDHL6  NI\0ZopHfW6ldHnvckBCe3OjeR?= MnfVNgKBkc7:TR?= NVTmdGRLPzJiaB?= MX7pcoR2[2W|IIPp[45q\mmlYX70JIFxd3C2b4TpZ{Bud3KyaH;sc4d6KGOqYX7n[ZMh[2:2cnXzeIVlKHerdHigRmNNOTGDIIPpVm5C MX6yOFk3OTZyNB?=
HCT-116 NYTuOGZCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2DMPWdKPTB;NTDuUS=> MlvWNlQ6Ojd6NUe=
SKNBe2C MmXXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1jGe2lEPTB;M{KuPOKyPC5yIH7N M3HjS|I1QTJzOUKw
IGNR91 NHLndI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYfJR|UxRTJ2LkRCtVEvPyCwTR?= NIS3ZoczPDl{MUmyNC=>
SKNAS MljLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NULOZVBJUUN3ME2xMlXDuTBwMjDuUS=> NIqweZozPDl{MUmyNC=>
LAN1 NFO2fW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFXPfo9KSzVyPUKuN:KyOC5{IH7N MW[yOFkzOTl{MB?=
SHSY5Y M4PBWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWjJR|UxRThwMtMxNE43KG6P M4DCfFI1QTJzOUKw
A549-WT NW\O[ZRqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUnafWxTUUN3ME2xPU41OzdiwsGgNE42QTRiIH7N M{LPUlI1QDV6OEK3
A549-R M4LwfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX7JR|UxRTF{LkG3PEDDuSByLkOzN{Ahdk1? MWmyOFg2QDh{Nx?=
MCF-7-WT NH\PN5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIfRboNKSzVyPUG3Mlc2OiEEsTCwMlIyQCBibl2= NUjlOoVEOjR6NUi4Nlc>
MCF-7-R M1fU[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWPONnJDUUN3ME21MlU{QSEEsTCwMlE1PCBibl2= M3[0V|I1QDV6OEK3
A549-R MkLHR5l1d3SxeHnjbZR6KEG|c3H5 MUfJR|UxRTF{LkG3PEDDuSByLkOzN{BvVQ>? M330WlI1QDV6OEK3
MCF-7-R NF\TbGpEgXSxdH;4bYNqfHliQYPzZZk> NYG4VGlvUUN3ME21MlU{QSEEsTCwMlE1PCCwTR?= NG\mUnQzPDh3OEiyOy=>
SW620 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2q5cWlEPTB;Nz64NEDDuSByLkC4JI5O NEfoO4kzPDd{NkezPS=>
SW620/AD300 M4jMfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGPpWZVKSzVyPUmwPU43OCEEsTC4MlkyKG6P NX:yWoJ5OjR5Mk[3N|k>
HEK293/pcDNA3.1 M1XRPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2SwemlEPTB;MT60OUDDuSByLkKwJI5O NFuzUJczPDd{NkezPS=>
HEK293/ABCC1 NUTKe291T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXHjVphYUUN3ME2xPU4zQSEEsTCyMlA5KG6P NXnwbFBNOjR5Mk[3N|k>
TCC NELiUHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV\hN5RyOjRiaB?= NHu2VoJKSzVyPUewJI5O NUTNcllvOjR5MU[5OFQ>
TCC MmK5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWS0PEBp MlPqTWM2OD13MDDuUS=> MV:yOFcyPjl2NB?=
HepG2/ADM NF3lOm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV;qOYtSUUN3ME2yMlc5PjQEsUCuNlM4OSEQvF2= MoDtNlQ4ODR3NU[=
HepG2 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkL1TWM2OD1yLkCxNVXDuTBwMECxO{DPxE1? M3X3bVI1PzB2NUW2
MCF-7/ADR M{Tqfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFzPTohKSzVyPUSuOFgzPsLzMD6yNFcxKM7:TR?= NEnWWFAzPDdyNEW1Oi=>
MCF-7 M1XLcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVP5fItWUUN3ME2wMlAyPToEsUCuNFA3OiEQvF2= Mo\INlQ4ODR3NU[=
A-172  NFewV3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFrI[ZUxNjIEoN88US=> M{X4cVI1Nzd{IHi= NYjVfWN[cW6qaXLpeJMh[2WubDDndo94fGhidHnt[UBl\XCnbnTlcpRtgQ>? NIC1cIUzPDV|MEKzOS=>
U-251MG MkXaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWiwMlHDqM7:TR?= NGDsOJYzPC95MjDo MXHpcohq[mm2czDj[YxtKGe{b4f0bEB1cW2nIHTldIVv\GWwdHz5 MWeyOFU{ODJ|NR?=
DLD-1 MmTMSpVv[3Srb36gRZN{[Xl? NILUNmYyODBibl2= MXS0PEBp NUPtUlJ6eHKxbX;0[ZMhWlWQWEOg[IVu\XSqeXzheIlwdsLi MWiyOFQxOzR3Mx?=
CCD18Co M{O4SmZ2dmO2aX;uJGF{e2G7 NEjmSJUyODBibl2= NGPGcmg1QCCq NF[3XJRxem:vb4Tld{BTXU6[MzDk[Y1mfGi7bHH0bY9vyqB? MWSyOFQxOzR3Mx?=
DLD-1 Ml6yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIDtfYYxNTFyMECgcm0> NW\Yfoo2PDhiaB?= NIPpSm5qdmirYnn0d{Bk\WyuIHfyc5d1cCCmb4PlJIRmeGWwZHXueIx6 NHnQcWozPDRyM{S1Ny=>
CCD18Co Mn;IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVqwMVExODBibl2= MYW0PEBp M3m0WIlvcGmkaYTzJINmdGxiZ4Lve5RpKGSxc3Wg[IVx\W6mZX70cJk> NX3TNWhzOjR2MEO0OVM>
HepG2 NIe1UJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXn1ZYJyOjRiaB?= MlnHTWM2OD13Mj615qCK|ryP M4e2VVI1OzRzNki4
HEK293/pcDNA3.1 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlHlTWM2OD1yLkCwOOKyOC5yMECzJO69VQ>? M3P3[|I1Ojh2N{iz
HEK293/MRP1 NV7ZRolOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYPJR|UxRTBwMEW1xtExNjBzMkCg{txO MnT5NlQzQDR5OEO=
Ramos NIi0OoxCeG:ydH;zbZMhSXO|YYm= MXWy5qCK|ryP MnX4OFghcA>? M4PleIlv\HWlZYOgN|QvPiYEsUGuPVImKGGyb4D0c5Nqew>? MX[yOFI2PjR7MR?=
NCI-H1299/pcDNA3 NGrrcXFE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MVuwMVIxKG6P MoHpPVYhcA>? NVjsZ5J5cW6qaXLpeJMh[2WubDD2bYFjcWyrdImg[I9{\SCmZYDlcoRmdnSueR?= M1fjblI1OTd5MEGy
H1299/ICAM-3 NHe1RZFE\WyuIG\pZYJqdGm2eTDBd5NigQ>? Mne4NE0zOCCwTR?= MWG5OkBp M{K0PYlvcGmkaYTzJINmdGxidnnhZoltcXS7IHTvd4Uh\GWyZX7k[Y51dHl? NGHsc4YzPDF5N{CxNi=>
NCI-H1299/pcDNA3 NGnpSlhHfW6ldHnvckBCe3OjeR?= M3jHWlEwPS9zMD:yNOKhdk1? MoPVPVYhcA>? NIXYPVBqdmS3Y3XzJINt\WG4YXflJI9nKGOjc4Dhd4V{NTNuIEisJFktKGGwZDDQRXJR M1HEOVI1OTd5MEGy
H1299/ICAM-3 MVHGeY5kfGmxbjDBd5NigQ>? NWLzU4ZNOS93L{GwM|IxyqCwTR?= MYq5OkBp NGXG[odqdmS3Y3XzJINt\WG4YXflJI9nKGOjc4Dhd4V{NTNuIEisJFktKGGwZDDQRXJR MnzlNlQyPzdyMUK=
W1 MoH5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH2xcHJKSzVyPUCuNFA{OiEQvF2= NFXRXWQzPDF2MEG3Oi=>
W1VR NHjhdVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXn4ZVY1UUN3ME2wMlA2PiEQvF2= NYPLTFlPOjRzNECxO|Y>
K562 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXSwUZNbUUN3ME2wMlA{OiEEsTCwMlAxOSBizszN MmTGNlQyOzV7M{e=
K562/ADR MmT6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MULJR|UxRTNwMk[xJOKyKDBwNEGyJO69VQ>? NYDxXYhKOjRzM{W5N|c>
K562 NFy3[5NCeG:ydH;zbZMhSXO|YYm= M2fhTlAvOyEQvF2= MlS1NlQhcA>? NXrDemV{cW6mdXPld{BieG:ydH;zbZMhe2mpbnnmbYNidnSueR?= MViyOFE{PTl|Nx?=
K562/ADR M2XwdmFxd3C2b4Ppd{BCe3OjeR?= MVmzJO69VQ>? NGrB[IwzPCCq NFjvTYRqdmS3Y3XzJIFxd3C2b4Ppdy=> M3rDNlI1OTN3OUO3
A549 NVvjNI5ST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXrJR|UxRTBwMUCgxtEhOC5yMzFOwG0> Ml:5NlM6PzFyN{W=
K562 Mm\WR4VtdCCYaXHibYxqfHliQYPzZZk> MlW0N{44PeLCk{[wxsBvVQ>? NHWzd2w4OsLiaNMg MoP5bY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliZH;z[UBl\XCnbnTlcpRtgQ>? MmXBNlM5Pzd{MkO=
lucena MoDGR4VtdCCYaXHibYxqfHliQYPzZZk> NUniS3ZOOy55NfMAl|YxyqCwTR?= MUi3NuKhcMLi MmPaco8h\W[oZXP0 NV65PHJxOjN6N{eyNlM>
FEPS MnnkR4VtdCCYaXHibYxqfHliQYPzZZk> NVG4UnQ1Oy55NfMAl|YxyqCwTR?= MnGxO|LDqGkEoB?= NX;YNng4dm9iZX\m[YN1 MmTFNlM5Pzd{MkO=
A2780 Mn[0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV;JR|UxRTNwNTDtUS=> NVPydnlmOjN6MkmyNFM>
ACHN NWHZW|NRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVXJR|UxRDBwMTDtUS=> Ml7MNlM5Ojl{MEO=
U-937 NVXtXXFOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXXDN3hQUUN3MEyzOEBvVQ>? MXSyN|gzQTJyMx?=
Jurkat NIPMPZNCeG:ydH;zbZMhSXO|YYm= MofBOeKh|rypL33sxsA> MnfwNlQhcA>? NHTVRlVqdmS3Y3XzJIFxd3C2b4Ppd{B{cWewaX\pZ4FvfGy7 NXXmZpFVOjN6MUC0NFk>
Jurkat NWezVGxtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn7VOeKh|rypL33sxsA> MnTzNlQhcA>? M3O0UoFzemW|dDDKeZJs[XRiY3XscJMhcW5iR{KvUUBxcGG|ZR?= MW[yN|gyODRyOR?=
Hep-2 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVLJR|UxRTBwMEVCtVAvODFizszN NX7xZZpLOjN5OEC0NlQ>
Hep-2/v NHPpVGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MULJR|UxRTFwONMxNE4zOCEQvF2= MWCyN|c5ODR{NB?=
SGC-7901 NIPjcXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIfiUW8xNTFyIN88[{9udA>? NHr5UJAzPC92OD:3NkBp NEjSSW1qdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDkc5NmKGGwZDD0bY1mKGSncHXu[IVvfCCvYX7u[ZI> NI\NRY0zOzd2M{W3Ni=>
SGC-7901/VCR MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXS3[Gd3OC1zMDFOwIcwdWx? M3WyR|I1NzR6L{eyJIg> M1vYdYlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHTvd4Uh[W6mIITpcYUh\GWyZX7k[Y51KG2jbn7ldi=> NETzTHgzOzd2M{W3Ni=>
SGC-7901 NWDvWoZ6SXCxcITvd4l{KEG|c3H5 M2HUO4lv\HWlZYOgZZBweHSxc3nzJJNq\26rZnnjZY51dHl? MVKyN|c1OzV5Mh?=
SGC-7901/VCR M1G2fWFxd3C2b4Ppd{BCe3OjeR?= MXHpcoR2[2W|IHHwc5B1d3OrczDzbYdvcW[rY3HueIx6 NHPEemkzOzd2M{W3Ni=>
KB-3-1 NEfOUFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2XMeWlEPTB;MT62OkDDuSByLkG2NkDPxE1? MmS2NlM3PzN2NEW=
KB-C2 Mn\mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHrqe4pKSzVyPUKwNk42PiEEsTC0Nk41QDFizszN M3nWZVI{Pjd|NES1
KB-3-1 M{HrdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUfYZm5TUUN3ME2xMlI3KMLzIECuNFI4KM7:TR?= NUj6ZYx1OjN4N{O0OFU>
KB-V1 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{XU[2lEPTB;MkC4Mlg2KMLzIEKwMlQh|ryP MVGyN|Y4OzR2NR?=
HEK293/pcDNA3.1 M2rRNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlzBTWM2OD1{ND6xJOKyKDBwMkC0JO69VQ>? NX7BdWdDOjN4N{O0OFU>
HEK293/ABCB1 MorjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVPZ[oRoUUN3ME2zOVEzNjhiwsGgN|c5NjN7MTFOwG0> MlO4NlM3PzN2NEW=
A549/EGFP  NXriTVlQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHPLXmYxNjBzLUGwNFAh|ryP M4PNXGlEPTB;OE[uO{DDuSB{OT6xJO69VQ>? M4nJVFI{PjN2Mkiy
A549/Slug M2SzOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1jCWVAvODFvMUCwNEDPxE1? MV;JR|UxRTlwNzFCtUA{NjFizszN NXrqfGpJOjN4M{SyPFI>
JFCR39  NHHW[W9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHrrTWgyKML3TR?= MlXhNlQhcA>? Ml\rSG1UVw>? NHvDdYlu[XKtZXTsfUBqdmO{ZXHz[ZMhfGinIH71cYJmeiCxZjDHNk9OKHCqYYPlJINmdGy| Moq2NlM2QTh{N{[=
A549 MnjYSpVv[3Srb36gRZN{[Xl? MmXNNVAxKG6P NWe4NI1uOTZiaB?= M3fwZmROW09? MXzs[YFleyC2bzDhJIxwe3Nib3[gcYlkem:2dXL1cIV{ MlLiNlM2QTh{N{[=
SGC7901 M3XsVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV3oZWlnUUN3ME2xMlI36oDLwsJihKkxNjFzIN88[{9udA>? Mly5NlM2PjR2OEK=
SGC7901/LV-NC NFXpV4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1HMfmlEPTB;MT63O-KBkcLz4pEJNE4yPiEQvHevcYw> NInY[nozOzV4NES4Ni=>
SGC7901/LV-SGO1 M3z4Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV\JR|UxRTRwM{dihKnDueLCiUCuN|ch|rypL33s NXzKbpFtOjN3NkS0PFI>
SGC7901/VCR NX73dIRnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYjJR|U{RTJyLkWz5qCKyrIkgJmxMlk3KM7:Zz;tcC=> NIfRWlEzOzV4NES4Ni=>
SGC7901/VCR-NC MlTwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mnz1TWM2OD1zOT64OwKBkcLz4pEJNk4xOSEQvHevcYw> MXmyN|U3PDR6Mh?=
SGC7901/VCR-si-SGO1 MoP0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlvVTWM2OD14LkG45qCKyrIkgJmxMlA{KM7:Zz;tcC=> Ml\5NlM2PjR2OEK=
SGC7901/ADR MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYrJR|UxRTdwOEZihKnDueLCiUCuOlQh|rypL33s MWGyN|U3PDR6Mh?=
SGC7901/ADR-NC MlTES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFzyZoZKSzVyPUiuPVPjiIoEsfMAjVAvPjhizsznM41t MUGyN|U3PDR6Mh?=
SGC7901/ADR-si-SGO1 Mn7xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHLtdoVKSzVyPUOuOFbjiIoEsfMAjVAvOjlizsznM41t MYWyN|U3PDR6Mh?=
SH-SY5Y  M2C4ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWXqSHZQOC5yMEGtNVAh|ryP Ml\GNlQhcA>? NFLNUJdKSzVyPUCuNVE{yrFyLkCxNkDPxE1? NV3DSZg6OjNzMkmwOlU>
SH-SY5Y  MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHTaSWsxNjByMT2xNEDPxE1? NF7NRmQ1QCCq MVjJR|UxRTBwMEe4xtExNjByOTFOwG0> NGrJW2kzOzF{OUC2OS=>
SH-SY5Y  M{KxUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3mzZ|AvODBzLUGwJO69VQ>? MXO3NkBp NV3hV5pJUUN3ME2wMlA2OcLzMD6wNFgh|ryP MUCyN|EzQTB4NR?=
SH-SY5Y NHHvSJRCeG:ydH;zbZMhSXO|YYm= NHrjTlExNjFizszN NI\ze|UxNTJ2IHi= M3HLeYlv\HWlZYOgZZBweHSxc3nzJI9nKFOKLWPZOXkh[2WubIOg[o9tdG:5aX7nJINmdGxiY4njcIUh[XK{ZYP0JIF1KHSqZTDHNk9OKHCqYYPl NEXsN2QzOzF{OUC2OS=>
SH-SY5Y MVPBdI9xfG:|aYOgRZN{[Xl? NU\vTXp5OC5zIN88US=> NETucnYxNTJ2IHi= MoP6bY5lfWOnczDtbZRwfGmlIHHydoV{fMLi NY\lSXNiOjNzMkmwOlU>

... Click to View More Cell Line Experimental Data

In vivo Vincristine (3 mg/kg) administrated by a single i.p. injection to mice bearing bilateral subcutaneous xenografts Rh12 or Rh18, induces mean growth delay of >120 and >52 day, and repopulating fractions of 0.06% and 5%, respectively. [6] Vincristine acts on subcutaneous colon 38 tumors in mice by host cell-mediated vascular effects as well as by direct tubulin-mediated cytotoxicity. Vincristine (5 mg/kg) reduces tumor blood flow of tumors by nearly 75% . [7]

Protocol

Cell Research:[1]
+ Expand
  • Cell lines: B16 melanoma cell
  • Concentrations: 10 nM
  • Incubation Time: 3 days
  • Method: Cells are plated in 2 mL of medium in 35-mm plates at a concentration of about 5 × 104 cells/mL and grow for 24 h at 37 ℃ in an atmosphere of 5% CO2 and 95% air. Then medium is replaced with fresh medium lacking or containing 4 nM drug and proliferation is continued for 3 days. Cell counts are done each day in a Coulter Counter after detaching the cells with trypsin and EDTA.
    (Only for Reference)
Animal Research:[6]
+ Expand
  • Animal Models: Human rhabdomyosarcoma xenografts Rh12
  • Formulation: Water solutioin
  • Dosages: 3 mg/kg
  • Administration: A single i.p. administration
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL (108.33 mM)
Water 60 mg/mL (65.0 mM)
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
Saline
For best results, use promptly after mixing.
30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 923.04
Formula

C46H58N4O14S

CAS No. 2068-78-2
Storage powder
in solvent
Synonyms Leurocristine

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03571321 Not yet recruiting Acute Lymphoblastic Leukemia|ALL Childhood|ALL University of Chicago|Incyte Corporation September 5 2019 Phase 1
NCT03349281 Recruiting Refractory Acute Lymphoblastic Leukemia|Relapsed Acute Lymphoblastic Leukemia Julio Barredo|Takeda|University of Miami March 2019 Phase 1
NCT03710772 Not yet recruiting CD20 Positive|Mantle Cell Lymphoma M.D. Anderson Cancer Center|National Cancer Institute (NCI) January 31 2019 Phase 2
NCT03613428 Not yet recruiting Acute T Cell Leukemia Sichuan University December 1 2018 Phase 1|Phase 2
NCT03742258 Not yet recruiting Diffuse Large B-Cell Lymphoma|Diffuse Large B-Cell Lymphoma Activated B-Cell Type|Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type|Diffuse Large B-Cell Lymphoma Not Otherwise Specified|High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements|High Grade B-Cell Lymphoma Not Otherwise Specified|T-Cell/Histiocyte-Rich Large B-Cell Lymphoma Northwestern University|National Cancer Institute (NCI) December 29 2018 Phase 1
NCT03704714 Not yet recruiting Aggressive Non-Hodgkin Lymphoma|B-Cell Non-Hodgkin Lymphoma|CD20 Positive|Diffuse Large B-Cell Lymphoma Unclassifiable|Intravascular Large B-Cell Lymphoma|Primary Mediastinal (Thymic) Large B-Cell Lymphoma|T-Cell/Histiocyte-Rich Large B-Cell Lymphoma|Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma Northwestern University|Bristol-Myers Squibb (BMS)|National Cancer Institute (NCI) November 8 2018 Phase 1|Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    I want to use the product #S1421 for mouse in vivo, could you please give us your advice about administration method?

  • Answer:

    According to the reference cited on our website, we test the solubility of S1421 Staurosporine in 4% DMSO/saline, and it is a suspension at 5 mg/mL. The compound can also be dissolved in the vehicle 4% DMSO/30% PEG 300/10% Tween 80/saline at 5 mg/ml as a clear solution for injection.

Microtubule Associated Signaling Pathway Map

Related Microtubule Associated Products0

Tags: buy Vincristine sulfate | Vincristine sulfate supplier | purchase Vincristine sulfate | Vincristine sulfate cost | Vincristine sulfate manufacturer | order Vincristine sulfate | Vincristine sulfate distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID